Label-Free Techniques for Drug Discovery: Surface Plasmon Resonance (SPR) and MALDI Mass Spectrometry for Primary (HTS) and Secondary Screening

The webinar will update on latest developments in MALDI mass spectrometry for high-throughput screening and CPD profiling (rapifleX MALDI PharmaPulse) and introduce Bruker's new surface plasmon resonance (SPR) instrument, the SIERRA SPR-32. Beside technical details explaining the latest developments, synergies between MALDI mass spectrometry and SPR will be discussed.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Overcoming Drug Resistance Patterns in Non-Responders: Proven Best Practices on Informing Your Clinical Strategy

xtalks

Many standard of care (SOC) treatments in cancer patients result in a clinical outcome of non-response. Drug development companies are trending toward interrogating resistance mechanisms and using this information in advancing their programs and informing personalized approaches to novel therapeutics.
Watch Now

Navigating data management challenges in the pharmaceutical life cycle

Eeuropeanpharmaceuticalreview

In this webinar, we introduce you to laboratory information management systems (LIMS) and demonstrate how this software can help you achieve regulatory compliance, quality data management throughout your product’s life cycle.
Watch Now

Targeted Cancer Chemotherapy: Developing NextGen Antibody-Drug Conjugates

labroots

In today's presentation I will give an overview to developing NextGen ADCs. We will discuss everything from the beginning stages of development to the varying ADC combination therapies available
Watch Now

Big Pharma Outlook 2026

pharmaintelligence

Datamonitor Healthcare’s Pharmavitae Analytics team casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals.
Watch Now

Spotlight

resources